Nagalingeswaran Kumarasamy
Overview
Explore the profile of Nagalingeswaran Kumarasamy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
258
Citations
7543
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vu T, Rupasinghe D, Khol V, Chaiwarith R, Tanuma J, Kumarasamy N, et al.
AIDS Res Ther
. 2025 Mar;
22(1):29.
PMID: 40038791
Introduction: Data on the impact of World Health Organization (WHO)'s guideline changes and COVID-19 on ART initiation in the Asia-Pacific remain scarce. This study described temporal trends from HIV diagnosis...
2.
Nagawa C, Selvamuthu P, Kumarasamy N, Balakrishnan F, Rigotti N, Kruse G
Tob Use Insights
. 2024 Dec;
17:1179173X241303587.
PMID: 39659298
Multiple tobacco product (MTP) use may intensify nicotine dependence and reduce the chances of quitting success. Characterizing MTP use in people with HIV (PWH) in low- and middle-income countries (LMICs)...
3.
Papot E, Tovar-Sanchez T, Woods J, Thaurignac G, Eriobu N, Borok M, et al.
AIDS
. 2024 Nov;
39(4):448-456.
PMID: 39576151
Objective: Data on the impact of coronavirus disease 2019 (COVID-19) in people with HIV (PWH) are lacking in resource-constrained settings. We utilized existing randomized clinical trials (RCTs) on antiretroviral therapies...
4.
Pinsky B, Sahoo M, Manasa J, Makadzange T, Wallis C, Marins E, et al.
J Clin Virol
. 2024 Nov;
175:105746.
PMID: 39566166
Background: The WHO HIV testing algorithm for high prevalence populations recommends the use of three different serologic assays, though this approach may lead to diagnostic misclassification. The study objective was...
5.
Global trends in CD4 count measurement and distribution at first antiretroviral treatment initiation
de Waal R, Wools-Kaloustian K, Brazier E, Althoff K, Jaquet A, Duda S, et al.
Clin Infect Dis
. 2024 Nov;
PMID: 39501773
Background: While people with HIV (PWH) start antiretroviral treatment (ART) regardless of CD4 count, CD4 measurement remains crucial for detecting advanced HIV disease and evaluating ART programmes. We explored CD4...
6.
Nimkar S, Kinikar A, Mave V, Khol V, Du Q, Nguyen L, et al.
HIV Med
. 2024 Sep;
26(1):140-152.
PMID: 39324422
Objective: We described mortality and loss to follow-up (LTFU) in children and adolescents who were under care for more than 5 years following initiation of antiretroviral therapy (ART). Methods: Patients...
7.
Rupasinghe D, Choi J, Kumarasamy N, Pujari S, Khol V, Somia I, et al.
J Viral Hepat
. 2024 Aug;
31(11):686-699.
PMID: 39115260
HCV RNA test determines current active infection and is a requirement prior to initiating HCV treatment. We investigated trends and factors associated with post-diagnosis HCV RNA testing rates prior to...
8.
Nasab S, Eniya M, Judith A, Clasen F, Faith B, Poongulali S, et al.
J Immunol Methods
. 2024 Jul;
532:113731.
PMID: 39059745
Innate and adaptive immune responses at mucosal surfaces play a role in protection against most infectious diseases. However, the relative importance either of mucosal versus systemic, or of cellular versus...
9.
Lee K, Jiamsakul A, Kiertiburanakul S, Borse R, Khol V, Yunihastuti E, et al.
PLoS One
. 2024 Jul;
19(7):e0306245.
PMID: 38950027
Introduction: Toxoplasma gondii can cause symptomatic toxoplasmosis in immunodeficient hosts, including in people living with human immunodeficiency virus (PLWH), mainly because of the reactivation of latent infection. We assessed the...
10.
Kingsley J, Kumarasamy N, Abrishamian L, Bonten M, Igbinadolor A, Mekebeb-Reuter M, et al.
Open Forum Infect Dis
. 2024 Jun;
11(6):ofae233.
PMID: 38854392
Background: The coronavirus disease 2019 (COVID-19) pandemic was characterized by rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, affecting viral transmissibility, virulence, and response to vaccines/therapeutics. EMPATHY...